JCN Newswire Eisai to Present at The Alzheimer’s Association International Conference (AAIC) 2022 Tagged in : alzheimer's data eisai from study
JCN Newswire U.S. FDA Accepts and Grants Priority Review for Eisai’s Biologics License Application of Lecanemab Tagged in : alzheimer's disease living priority with
JCN Newswire Eisai Completes Rolling Submission to the U.S. FDA for Biologics License Application of Lecanemab for Early Alzheimer’s Disease Under the Accelerated Approval Pathway Tagged in : alzheimer's disease lecanemab study with
JCN Newswire Eisai to Present New Lecanemab Data Exploring Distinct Mechanism of Action and Clinical Outcomes, Disease State (DSE) Symposium, and Other Pipeline Assets at the AD/PD 2022 Annual Meeting Tagged in : alzheimer's clinical disease early eisai's
JCN Newswire Eisai: Update on the Phase 4 ENVISION Confirmatory Study of ADUHELM Tagged in : alzheimer's clinical disease trials with
JCN Newswire Eisai’s Anti-amyloid Beta Protofibril Antibody Lecanemab Selected as the Background Therapy for the Tau Nexgen Study Tagged in : alzheimer's clinical disease nexgen study
JCN Newswire Eisai Presents New Analysis of Lecanemab Clinical Efficacy Results from Phase 2b Study at Clinical Trials On Alzheimer’s Disease (CTAD) Conference Tagged in : alzheimer's clinical efficacy lecanemab study
JCN Newswire Eisai: New Phase 3 Data Show Positive Correlation Between ADUHELM Treatment Effect on Biomarkers and Reduction in Clinical Decline in Alzheimer’s Disease Tagged in : aduhelm alzheimer's disease p-tau181 plasma
JCN Newswire Eisai: DIAN-TU Selects Lecanemab as Background Anti-Amyloid Therapy in Clinical Trial Evaluating Investigational Therapy Targeting Tau for Dominantly Inherited Alzheimer’s Disease Tagged in : alzheimer's clinical disease inherited study
JCN Newswire Eisai Presents New Data on the Relationship Between Clinical, Biomarker and Safety Outcomes from the Lecanemab Phase 2B Study Tagged in : alzheimer's disease eisai's investigational lecanemab
JCN Newswire Biogen and Eisai Announce Design of ADUHELM ICARE AD-US Study, the First Real-World Observational Phase 4 Study in Alzheimer’s Disease at AAIC 2021 Tagged in : ad-us alzheimer's disease study with
JCN Newswire Biogen and Eisai Announce ADUHELMTM (aducanumab-avwa) Data Presentations at Alzheimer’s Association International Conference 2021 Tagged in : alzheimer's clinical disease treatment with
JCN Newswire Eisai to Present Latest Data on Pipeline Assets in The Area of Alzheimer’s Disease and Dementia at AAIC 2021 Tagged in : alzheimer's clinical disease study will
JCN Newswire Biogen and Eisai launch initiatives to help patients with Alzheimer’s disease access ADUHELM Tagged in : aduhelm alzheimer's disease patients with
JCN Newswire FDA grants accelerated approval for ADUHELM as the first and only Alzheimer’s disease treatment to address a defining pathology of the disease Tagged in : aduhelm alzheimer's disease patients with
JCN Newswire Notice Regarding Biogen’s Disclosure About the Submission of Marketing Authorization Applications in Brazil, Canada, Australia, and Switzerland for Aducanumab for Alzheimer’s Disease Tagged in : aducanumab alzheimer's applications disease investigational
JCN Newswire Eisai: 18-Month, Pre-Specified Analysis Showing Consistent Reduction in Clinical Outcome Measures from a Lecanemab (BAN2401) Phase 2b Clinical Trial in Early Alzheimer’s Disease Tagged in : alzheimer's clinical disease phase trial
JCN Newswire Eisai: Anti-MTBR (Microtubule Binding Region) Tau Antibody E2814 is Selected on Clinical Study for Dominantly Inherited Alzheimer’s Disease by Dian-Tu Tagged in : alzheimer alzheimer's disease dominantly inherited
JCN Newswire Eisai to Present Latest Data on Pipeline Assets in the Area of Alzheimer’s Disease and Dementia at the 15th International Conference on Alzheimer’s and Parkinson’s Disease Tagged in : alzheimer's data dementia disease parkinson's
JCN Newswire Eisai: Biogen Files New Drug Application for Aducanumab in Japan Tagged in : aducanumab alzheimer's disease review with
